Market Cap 9.99B
Revenue (ttm) 0.00
Net Income (ttm) -600.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.13
Volume 1,972,600
Avg Vol 2,096,992
Day's Range N/A - N/A
Shares Out 186.93M
Stochastic %K 81%
Beta 1.27
Analysts Strong Sell
Price Target $77.21

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6801
Address:
700 Saginaw Drive, Redwood City, United States
BillionerOfKing
BillionerOfKing Oct. 24 at 5:50 PM
$RVMD Current Stock Price: $54.44 Contracts to trade: $55 RVMD Nov 21 2025 Call Entry: $1.70 Exit: $3.19 ROI: 88% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 12:21 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RVMD Current Share Price: $53.26 Contracts: $RVMD January 15, 2027 $60 Calls Scale in: $11.93- $14.58 Scale out: $18.55-$23.85 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Prosperity1_
Prosperity1_ Oct. 23 at 3:27 AM
0 · Reply
bet_on_biotechs
bet_on_biotechs Oct. 22 at 11:55 PM
$IMRX The key question arises: Where is an investor likely to have a better chance of making money – with $RVMD or $IMRX? In the long term, there is absolutely no news about RVMD that could lead to a doubling of the SP. This is based on the lack of logic behind the scenario of simply multiplying an existing MCAP of $10 billion by $20 billion. Neither an assumed FDA approval nor initial product sales potentially received by RVMD will achieve this. From now on, the performance for speculators would no longer be satisfactory. Any significantly undervalued stock is likely to deliver better – and faster – performance. Let's compare IMRX – here, every positive news item likely brings with it the chance of topping RVMD's future annual performance. Simple theory – but one that will prove true.
0 · Reply
saulhernandez59
saulhernandez59 Oct. 22 at 6:49 PM
$RVMD Keeping entries aligned with invalidation
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:47 PM
Mizuho has adjusted their stance on Revolution Medicines ( $RVMD ), setting the rating to Outperform with a target price of 90.
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:20 PM
Mizuho🏁 $RVMD Outperform/$90 $ZLAB AMGN BMY VSTM $IMRX Mizuho in its initiation report said: We see RVMD's portfolio of RAS(ON) inhibitors as positioned to play significant roles in PDAC, NSCLC and CRC. Specifically, we believe daraxonrasib in PDAC alone and additional near-term de-risking can drive meaningful upside. First, we expect future 1L PDAC updates and insights into PFS/OS to mature favorably and drive greater conviction around the Phase III RASolute 303 study. Second, scenario modeling of the Phase III RAsolute 302 trial in 2L PDAC points to a high probability of success, and we believe control arm overperformance, daraxonrasib underperformance and high drop out are all needed to put the study at risk. Altogether, the portfolio could generate $10B+ in risk-adjusted 2035 WW sales. We expect positive Phase III 2L PDAC data in 2026, and additional earlier-stage updates to drive outperformance over the next 12 months.
0 · Reply
JFais
JFais Oct. 20 at 3:03 PM
Am wary of situations where the bar is already high (much of oncology is already there, $RVMD now doing that for pancreatic) White space is still there (ie. endometrial post PD-1), but increasingly harder to find
0 · Reply
JFais
JFais Oct. 20 at 2:41 PM
Agree with Houbi re $RVMD vs $VSTM in KRAS
2 · Reply
Latest News on RVMD
Revolution Medicines: Risky Buy On Recent Share Price Dip

Dec 4, 2024, 9:09 AM EST - 11 months ago

Revolution Medicines: Risky Buy On Recent Share Price Dip


Top 3 Health Care Stocks That Could Blast Off In December

Dec 4, 2024, 6:15 AM EST - 11 months ago

Top 3 Health Care Stocks That Could Blast Off In December

ELAN SHC


BillionerOfKing
BillionerOfKing Oct. 24 at 5:50 PM
$RVMD Current Stock Price: $54.44 Contracts to trade: $55 RVMD Nov 21 2025 Call Entry: $1.70 Exit: $3.19 ROI: 88% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 12:21 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RVMD Current Share Price: $53.26 Contracts: $RVMD January 15, 2027 $60 Calls Scale in: $11.93- $14.58 Scale out: $18.55-$23.85 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Prosperity1_
Prosperity1_ Oct. 23 at 3:27 AM
0 · Reply
bet_on_biotechs
bet_on_biotechs Oct. 22 at 11:55 PM
$IMRX The key question arises: Where is an investor likely to have a better chance of making money – with $RVMD or $IMRX? In the long term, there is absolutely no news about RVMD that could lead to a doubling of the SP. This is based on the lack of logic behind the scenario of simply multiplying an existing MCAP of $10 billion by $20 billion. Neither an assumed FDA approval nor initial product sales potentially received by RVMD will achieve this. From now on, the performance for speculators would no longer be satisfactory. Any significantly undervalued stock is likely to deliver better – and faster – performance. Let's compare IMRX – here, every positive news item likely brings with it the chance of topping RVMD's future annual performance. Simple theory – but one that will prove true.
0 · Reply
saulhernandez59
saulhernandez59 Oct. 22 at 6:49 PM
$RVMD Keeping entries aligned with invalidation
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:47 PM
Mizuho has adjusted their stance on Revolution Medicines ( $RVMD ), setting the rating to Outperform with a target price of 90.
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:20 PM
Mizuho🏁 $RVMD Outperform/$90 $ZLAB AMGN BMY VSTM $IMRX Mizuho in its initiation report said: We see RVMD's portfolio of RAS(ON) inhibitors as positioned to play significant roles in PDAC, NSCLC and CRC. Specifically, we believe daraxonrasib in PDAC alone and additional near-term de-risking can drive meaningful upside. First, we expect future 1L PDAC updates and insights into PFS/OS to mature favorably and drive greater conviction around the Phase III RASolute 303 study. Second, scenario modeling of the Phase III RAsolute 302 trial in 2L PDAC points to a high probability of success, and we believe control arm overperformance, daraxonrasib underperformance and high drop out are all needed to put the study at risk. Altogether, the portfolio could generate $10B+ in risk-adjusted 2035 WW sales. We expect positive Phase III 2L PDAC data in 2026, and additional earlier-stage updates to drive outperformance over the next 12 months.
0 · Reply
JFais
JFais Oct. 20 at 3:03 PM
Am wary of situations where the bar is already high (much of oncology is already there, $RVMD now doing that for pancreatic) White space is still there (ie. endometrial post PD-1), but increasingly harder to find
0 · Reply
JFais
JFais Oct. 20 at 2:41 PM
Agree with Houbi re $RVMD vs $VSTM in KRAS
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 10:43 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RVMD Current Share Price: $54.10 Contracts: $RVMD January 15, 2027 $60 Calls Scale in: $12.15- $14.84 Scale out: $18.89-$24.29 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Power2k
Power2k Oct. 18 at 3:57 PM
$IMRX I think this is the new $RVMD in the making and is positioned as a potential buyout target. RVMD is very likely to go it alone as they recently got 2B funding from Royalty Pharma and the chance of acquisition is very slim, plus its MC already reaches 10b range. As a contrast, multiple BPs showed interests in and formed partnerships with us, $LLY, $REGN and of course $SNY . Don't forget that Roche and AstraZeneca are also developing MEK inhibitors in their pipelines and could very likely be interested in acquiring IMRX if Atebi maintains high level of efficacy (long mOS/mPFS vs SOC) in future data readouts. We are much smaller and a bit behind compared to RVMD, but we are a very strong contender in the PDAC space and BPs acknowledge that. Sanofi injected 25M for a good reason. Just my two cents. GLTA!
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 1:47 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RVMD Current Share Price: $49.68 Contracts: $RVMD January 15, 2027 $50 Calls Scale in: $11.83- $14.45 Scale out: $18.40-$23.65 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
History101
History101 Oct. 18 at 12:21 AM
$SLS Just imagine if SLS receives one of the new FDA accelerated vouchers like the one annonced today for $RVMD https://finance.yahoo.com/news/revolution-medicines-awarded-voucher-daraxonrasib-000000829.html
1 · Reply
dominicksolis22
dominicksolis22 Oct. 17 at 7:14 PM
$RVMD Watch liquidity metrics on Oct 22 and Oct 23 and Oct 24. Volume spikes after 1x1 schedules are common. If volume climbs 2x to 4x average and price holds higher lows that is institutional accumulation behavior
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 4:54 PM
Enter: $RVMD NOV 21 2025 $50 CALLS Buy in Price: $2.40 - $4.60 Take Profit: $5.14 Stop Bleeding: $2.11 ROI Potential: 114% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 4:34 PM
Raymond James has updated their rating for Revolution Medicines ( $RVMD ) to Strong Buy with a price target of 76.
0 · Reply
topstockalerts
topstockalerts Oct. 17 at 3:57 PM
$RVMD Is it going higher? Comment below..
0 · Reply
topstockalerts
topstockalerts Oct. 17 at 3:28 PM
$RVMD sector heating up.. stay tuned!
0 · Reply
Quantumup
Quantumup Oct. 17 at 3:09 PM
Raymond James⬆️ $RVMD's PT to $76 from $72/keeps at a Strong Buy after RevMed was included in the FDA's NPVR program. $ZLAB $AMGN $BMY VSTM $IMRX BofA⬆️to $80 from $78/reit'd Buy-Top Pick after RevMed was awarded one of the nine NPRVs for daraxonrasib in PDAC. Raymond James and BofA said in their notes to investors:
3 · Reply
topstockalerts
topstockalerts Oct. 17 at 2:30 PM
$RVMD following closely 👀
0 · Reply
MaverikIT
MaverikIT Oct. 17 at 2:24 PM
@IsabellaDC @TheLongVol taking your $IRON this AM ? $RVMD
0 · Reply